Evidence map›Paper›PMID 36372074›Full record

ArticleLancet (London, England)2022

WHO Living Guidelines on antivirals for COVID-19 are evidence-based.

Andrew Owen, Janet Victoria Diaz, Gordon Guyatt, François Lamontagne, Miriam Stegemann, Per Olav Vandvik, Thomas Agoritsas

Open access · greenAbstract readLetterComment
In one paragraph

Article in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Andrew OwenCentre of Excellence in Long-acting Therapeutics, Department of Pharmacology and Therapeutics, Materials Innovation Factory, University of Liverpool, Liverpool L7 3NY, UK. Electronic address: aowen@liverpool.ac.uk.
Janet Victoria DiazWorld Health Organization, Geneva, Switzerland.
Gordon GuyattDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
François LamontagneDepartment of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada.
Miriam StegemannDepartment of Infectious Diseases and Respiratory Medicine Berlin, Charité-Universitätsmedizin Berlin, Germany.
Per Olav VandvikMAGIC Evidence Ecosystem Foundation, Oslo, Norway.
Thomas AgoritsasDepartment of Medicine, University Hospitals of Geneva, Geneva, Switzerland.
Impact · CAUniversité de Sherbrooke · CAUniversity Hospital of Geneva · CHWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Antiviral AgentsHumansSARS-CoV-2World Health OrganizationAntiviral Agents

Identifiers

PMID36372074
PMCPMC9648976
OpenAlexW4308698229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.